candesartan has been researched along with Cerebral Hemorrhage in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed the effects of treatment with candesartan in acute ICH and according to different types of hematoma." | 9.30 | Effects of Candesartan in the Acute Phase of Intracerebral Hemorrhage. ( Anderson, C; Bath, PM; Berge, E; Berge, TE; Delcourt, C; Guo, R; Jusufovic, M; Karlson, BW; Sandset, EC; You, S, 2019) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke." | 9.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 9.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| " We assessed the effects of treatment with candesartan in acute ICH and according to different types of hematoma." | 5.30 | Effects of Candesartan in the Acute Phase of Intracerebral Hemorrhage. ( Anderson, C; Bath, PM; Berge, E; Berge, TE; Delcourt, C; Guo, R; Jusufovic, M; Karlson, BW; Sandset, EC; You, S, 2019) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke." | 5.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke." | 5.16 | Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. ( Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 5.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jusufovic, M | 2 |
| Berge, TE | 1 |
| Guo, R | 1 |
| You, S | 1 |
| Delcourt, C | 1 |
| Anderson, C | 1 |
| Bath, PM | 4 |
| Karlson, BW | 1 |
| Berge, E | 4 |
| Sandset, EC | 4 |
| Boysen, G | 1 |
| Jatuzis, D | 1 |
| Kõrv, J | 1 |
| Lüders, S | 1 |
| Murray, GD | 2 |
| Richter, PS | 1 |
| Roine, RO | 1 |
| Terént, A | 1 |
| Thijs, V | 1 |
| Kjeldsen, SE | 1 |
| Fukui, T | 1 |
| Rahman, M | 1 |
| Hayashi, K | 1 |
| Takeda, K | 1 |
| Higaki, J | 1 |
| Sato, T | 1 |
| Fukushima, M | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Ogihara, T | 1 |
| Fukiyama, K | 1 |
| Fujishima, M | 1 |
| Saruta, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Cerebral Hemorrhage
| Article | Year |
|---|---|
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio | 2003 |
4 trials available for candesartan and Cerebral Hemorrhage
| Article | Year |
|---|---|
Effects of Candesartan in the Acute Phase of Intracerebral Hemorrhage.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2019 |
Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2016 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2012 |